News | Neuro Imaging | August 30, 2018

NIH-funded trial offers hope for disease with limited treatment options

Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.


August 30, 2018 — Results from a clinical trial of more than 250 participants with progressive multiple sclerosis (MS) revealed the drug ibudilast was better than a placebo in slowing down brain shrinkage. The study also showed that the main side effects of ibudilast were gastrointestinal and headaches.

The study was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and published in the New England Journal of Medicine.1

“These findings provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options,” said Walter J. Koroshetz, M.D., director of the NINDS.

MS occurs when there is a breakdown of myelin, a fatty white substance wrapped around axons, which are long strands that carry messages from and between brain cells. When myelin starts to break down, communication between brain cells slows down, leading to muscle weakness and problems with movement, balance, sensation and vision. MS can be relapsing-remitting, in which symptoms occur then disappear for weeks or months and then may reappear, or progressive, which is marked by a gradual decline in function.

Robert J. Fox, M.D., a neurologist at Cleveland Clinic in Ohio, led a team of researchers across 28 clinical sites in a brain imaging study. They were investigating whether ibudilast was better than placebo in reducing the progression of brain atrophy, or shrinkage, in patients with progressive multiple sclerosis.

In the study, 255 patients were randomized to take up to 10 capsules of ibudilast or placebo per day for 96 weeks. Every six months, the participants underwent magnetic resonance imaging (MRI) brain scans. Fox’s team applied a variety of analysis techniques on the MRI images to assess differences in brain changes between the two groups.

The study showed that ibudilast slowed down the rate of brain atrophy compared to placebo. Fox and his colleagues discovered that there was a difference in brain shrinkage of 0.0009 units of atrophy per year between the two groups, which translates to approximately 2.5 milliliters of brain tissue. In other words, although both groups experienced atrophy, the brains of the patients in the placebo group shrank on average 2.5 milliliters more over two years compared to the ibudilast group. The whole adult human brain has a volume of approximately 1,350 milliliters. However, it is unknown whether that difference had an effect on symptoms or loss of function.

There was no significant difference between the groups in the number of patients who reported adverse effects. The most common side effects associated with ibudilast were gastrointestinal, including nausea and diarrhea, as well as headaches and depression.  

“The trial’s results are very encouraging and point towards a potential new therapy to help people with progressive MS,” said Fox. “It also increased our understanding of advanced imaging techniques, so that future studies may require a smaller number of patients followed over a shorter period of time. This leads to increased efficiency of clinical research. These imaging methods may also be relevant to a host of other neurological disorders.”

Future research will test whether reducing brain shrinkage affects thinking, walking and other problems in people with MS. In addition, future studies will examine whether ibudilast slows the progression of disability in MS patients.  

For more information: www.nejm.org

Reference

1. Fox R.J., Coffey C.S., Conwit R., et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, Aug. 30, 2018. DOI: 10.1056/NEJMoa1803583

 

Related Content

News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Radiology Business

September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software ...

Time September 27, 2021
arrow
News | Prostate Cancer

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Time September 23, 2021
arrow
News | Women's Health

September 22, 2021 — Radiation therapy is an effective and widely used treatment for breast cancer. While the benefits ...

Time September 22, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
News | Contrast Media Injectors

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
News | Lung Imaging

September 15, 2021 — Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial ...

Time September 15, 2021
arrow
Subscribe Now